Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

News and Trends 29 Jun 2016

Vienna-based Biotech raises €10M to fight Metabolic diseases and Parkinson’s

AFFiRiS has received €10M from previous investors and one additional backer, adding up to €130M in total funding (half from grants and licensing incomes). This money fuels a pipeline in cardiometabolic and neurodegenerative diseases as more candidates break into clinical development. Based at the Campus Vienna Biocenter (Austria), AFFiRiS is developing immunotherapies to prevent chronic diseases. […]

June 29, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 29 Jun 2016

Cell Therapy for Heart Failure fails in Phase III … but not Entirely

Celyad failed to get significant results in its Phase III trial in cardiac disease. However, this cell therapy could still have a positive effect in a part of the patients. True potential or public relations patch? Cardiovascular diseases are the leading cause of death worldwide. Biotech solutions in the field range from gene therapy (with uniQure and […]

June 29, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 29 Jun 2016

How to Survive the Valley of Death as a Biotech Startup?

Over the past decade there has been an unprecedented restructuring of R&D in pharma whereas building a successful biotech company is still as challenging. How can these two elements help each other? This is a contributing post from Peter Machin, former SVP Drug Discovery at GSK. Big Pharma has significantly contracted its in-house […]

June 29, 2016 - 5 minutesmins - By External Contributor

News and Trends 28 Jun 2016

And now, Immuno-oncology gets EMA’s pre-approval for Lung Cancer

MSD has received EMA pre-approval for its famous anti-PD-1 therapy, Keytruda. It could soon be used to treat non-small cell lung cancer (NSCLC), the deadliest type of cancer. Checkpoint inhibitors are a key strategy in the hype field of immuno-oncology. This kind of cancer therapy blocks the natural ‘safety checks’ of the immune system – […]

June 28, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 28 Jun 2016

What’s the Truth about Gender Diversity in Biotech?

The diversity debate in biotech has always been there. In the month of Pride and after LifeSci’s party scandal at JPMorgan 2016, I was wondering what’s the real situation about diversity in biotech? And what could be the solutions? Haven’t you heard about the LifeSci’s party scandal? In short: the editor of BioCentury Karen Bernstein […]

June 28, 2016 - 5 minutesmins - By Philip Hemme

News and Trends 28 Jun 2016

Will the Leading Italian Biotech soon have its First Cell therapy on the Market?

MolMed has received conditional market approval for Zalmoxis, an ex vivo genetically engineered cell therapy that stops immune rejection of transplanted hematopoietic stem cells. This is a big step forward in a key treatment for blood cancers. A transplant of hematopoietic stem cells (cells that give origin to blood cells) is often used as part of treatments for […]

June 28, 2016 - 2 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT

News and Trends 27 Jun 2016

CRISPR Therapeutics increases its Series B to a Massive €125M

Everyone wants to invest in CRISPR Therapeutics, it seems. The Basel and Cambridge, US biotech has raised more money for its ongoing Series B round, bringing the total to over €126M. The authorization for the first CRISPR trials have just arrived in the hands of the FDA, and this might have encouraged new investment. CRISPR Therapeutics […]

June 27, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 27 Jun 2016

Genticel is facing hard Times Again!

As presented last week, Genticel was getting back on track with the announcement of two major milestones with the aim to prepare the phase III. However, the major outcomes of its Phase II were expected to be presented on the 17th of June at Eurogin 2016 Congress… Here they are (and they are really bad)! GTL001 is […]

June 27, 2016 - 2 minutesmins - By Jerome Topsent

News and Trends 27 Jun 2016

“France has always been a Leader in Infectious Disease and Microbiology”

This is what Franck Lescure, a partner at VC firm Auriga Partners, told me when I met him in Paris at his office next to the Champs-Elysées. Their last fund, Auriga IV Bioseeds, focuses on infectious disease and microbiology, with 6 investments so far and 9 by the end of 2016. It was a great way to […]

June 27, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 25 Jun 2016

How to do art with 9000 Petri Dishes? Julia Lohmann’s BioArt

Julia Lohmann grew up in the German countryside, studied design in England and worked on a farm in Iceland. Now as a designer and researcher, she brings all these experiences to her work – with maggots, bacteria, algae and 9000 petri dishes. Julia Lohmann started with sculpture by collecting driftwood during her childhood in Hildesheim, in […]

June 25, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 24 Jun 2016

Why would Snow-growing Algae be killing Glaciers?

Red Algae bloom on glaciers during summer, which may give the snow more than a nice pink shade. The darker color makes the glacier melt faster – a previously overlooked mechanism in climate change. In biotech, algae almost became synonymous with unlimited potential, including as a promising new generation of biofuels – so they should be pretty environment-friendly, right? […]

June 24, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 24 Jun 2016

#Brexit: Sad news for the UK Biotech scene…

The first thing I checked this morning was the outcome of the Brexit vote, and what sad news when I read Brexit won. It was close, but the only thing that matters is the end result. Now, what will be the impact of such a vote on the UK biotech scene? The result will be significant, […]

June 24, 2016 - 5 minutesmins - By Joachim Eeckhout

ADVERTISEMENT